Operator of a therapeutics company with a platform of novel disease-modifying regenerative small molecules being developed with the potential to stop disease progression and even restore lost function. M3 has advanced a lead candidate for Alzheimer's disease to first-in-human Phase I clinical trials assessing safety, toxicity and tolerability while also evaluating a novel biomarker for AD. The company's solutions act on trophic factors of a highly conserved mechanism of action. The core technology and lead candidate has the potential to address neurodegenerative therapies broadly. The company has optimized a lead compound for a first indication in AD, launched clinical trials and expanded the therapeutics pipeline.